FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements

On August 26, 2011, crizotinib received accelerated approval for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by a test approved by the U.S. Food and Drug Administration (FDA). Approval was based on two single-arm t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kazandjian, Dickran, Blumenthal, Gideon M., Chen, Huan-Yu, He, Kun, Patel, Mona, Justice, Robert, Keegan, Patricia, Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201002/
https://ncbi.nlm.nih.gov/pubmed/25170012
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0241
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados